Clinical trial
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
NCT00549718
Study timeline
Study start (unknown)2007-10-01Date precision: month
Registry last updated2014-06-11
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Schizophreniaunresolved
Interventions
Lurasidone HClDRUG
Sponsors & collaborators
Sumitomo Pharma America, Inc.lead sponsor
Mapped research locations
Saint PetersburgRussia5BucharestRomania2PhiladelphiaPennsylvania, United States1AtlantaGeorgia, United States1San DiegoCalifornia, United States1Washington D.C.District of Columbia, United States1AustinTexas, United States1MemphisTennessee, United States1Little RockArkansas, United States1BuffaloNew York, United States1BrooklynNew York, United States1KyivUkraine1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00549718 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.